6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December, 2007.

Commission File Number 000-51341

 Gentium S.p.A.  
(Translation of registrant’s name into English)

Piazza XX Settembre 2, 22079 Villa Guardia (Como), Italy   
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x    Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
 
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes o No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
82-_______________.
 

The Registrant's press releases, quarterly report for the period ended September 30, 2007 and certain contracts are attached hereto as Exhibits 99.1, 99.2, 99.3, 99.4, 99.5 and 99.6 and incorporated by reference herein in their entirety. This report and the exhibits attached thereto are incorporated by reference into the registration statements of Gentium S.p.A. on Forms S-8, File No. 333-137534 and File No. 333-146534 and on Forms F-3: File No. 333-135622, File No. 333-137551, File No. 333-138202, File No. 333-139422 and File No. 333-141198.
 
Exhibit
 
Description
     
 
Press release, dated December 7, 2007.
     
 
Press release, dated December 11, 2007.
     
 
Quarterly report for the period ended September 30, 2007.
     
 
Letter Agreement, dated October 12, 2007, between Gentium S.p.A. and Sigma-Tau Pharmaceuticals Inc.
     
 
Manufacturing Agreement, dated November 30, 2007, between Gentium S.p.A and Sirton Pharmaceuticals S.p.A.
     
 
Amendment No. 1 to Active Ingredient Supply Agreement, effective as of December 7, 2007 by and between Gentium S.p.A. and Sirton Pharmaceuticals S.p.A.
 

SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     
 
GENTIUM S.P.A.
 
 		  
 		  
 
By:   /s/ Gary G. Gemignani    
 
Name: Gary G. Gemignani
Title: Chief Financial Officer
 
Date: December 11, 2007
 

INDEX TO EXHIBITS

Exhibit
 
Description
     
 
Press release, dated December 7, 2007.
     
 
Press release, dated December 11,2007.
     
 
Quarterly report for the period ended September 30, 2007.
     
 
Letter Agreement, dated October 12, 2007, between Gentium S.p.A. and Sigma-Tau Pharmaceuticals Inc.
     
 
Manufacturing Agreement, dated November 30, 2007, between Gentium S.p.A and Sirton Pharmaceuticals S.p.A.
     
 
Amendment No. 1 to Active Ingredient Supply Agreement, effective as of December 7, 2007 by and between Gentium S.p.A. and Sirton Pharmaceuticals S.p.A.